{
  "source": "PA-Notification-Cuvrior.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1401-4\nProgram Prior Authorization/Notification\nMedication Cuvrior™ (trientine tetrahydrochloride)*\nP&T Approval Date 1/2023, 1/2024, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nCuvrior* (trientine tetrahydrochloride) is a copper chelator indicated for the treatment of adult\npatients with Wilson’s disease who are de-coppered and tolerant to penicillamine.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Cuvrior* will be approved based on all of the following criteria:\na. Diagnosis of Wilson’s disease\n-AND-\nb. Patient is de-coppered [i.e., serum non-ceruloplasmin copper (NCC) level ≥ 25 and\n≤ 150 mcg/L]\n-AND-\nc. Patient is tolerant to penicillamine\n-AND-\nd. Patient will discontinue penicillamine before starting therapy with Cuvrior\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Cuvrior* will be approved based upon the following criterion:\na. Documentation of positive clinical response to Cuvrior therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2025 UnitedHealthcare Services, Inc.\n1\n*Cuvrior is typically excluded from coverage. Tried/Failed criteria may be in place. Please refer to\nplan specifics to determine exclusion status.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Cuvrior [package insert]. Chicago, IL: Orphalan; April 2022.\nProgram Prior Authorization/Notification – Cuvrior (trientine tetrahydrochloride)\nChange Control\n1/2023 New p",
    "e in place.\n4. References:\n1. Cuvrior [package insert]. Chicago, IL: Orphalan; April 2022.\nProgram Prior Authorization/Notification – Cuvrior (trientine tetrahydrochloride)\nChange Control\n1/2023 New program.\n1/2024 Annual review with no changes to coverage criteria.\n2/2024 Annual review. Added footnote indicating Cuvrior is typically\nexcluded from coverage. Updated authorization durations to 12\nmonths.\n2/2025 Annual review with no changes to coverage criteria.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}